At The 2016 Global Ibogaine Conference:
“Phytostan Pharmaceuticals, Genesis Ibogaine Center, Nutra Lab Canada Ltd., Patient ‘D’ and CKBR-12 have conducted the first treatment anywhere of a Parkinson’s Patient with an Ibogaine Derivative Medication. The results are astounding.”
“both ibogaine and its metabolite noribogaine have been shown to lead to an increase in levels of glial cell line-derived neurotrophic factor (GDNF) in the brain. It has also been shown to have neuroprotective qualities promoting the survival of both dopaminergic and motor neurons.
In other research, neurotrophic factors, specifically GDNF, have been shown to cause sprouting of dopaminergic fibers, with a resulting improvement of clinical symptoms of Parkinson’s in experimental animal models and humans”